Thymoma and Thymic Carcinoma

Protocol applies to thymic epithelial tumors located in any area of the mediastinum.

Protocol revision date: January 2005
No AJCC/UICC staging system

Procedures
• Biopsy
• Resection

Authors
Alberto Marchevsky, MD
Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California
M. Elizabeth H. Hammond, MD
Department of Pathology, LDS Hospital and University of Utah School of Medicine, Salt Lake City, Utah
Cesar Moran, MD
M.D. Anderson Cancer Center, Houston, Texas
Saul Suster, MD
Department of Pathology, Ohio State University School of Medicine, Columbus, Ohio

For the Members of the Cancer Committee, College of American Pathologists
Thymoma and Thymic Carcinoma • Thorax

© 2005. College of American Pathologists. All rights reserved.
The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary (Checklist)” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.
Summary of Changes to Checklist(s)

Protocol revision date: January 2005

No changes have been made to the data elements of the checklist(s) since the January 2004 protocol.
Thymoma and Thymic Carcinoma • Thorax

Surgical Pathology Cancer Case Summary (Checklist)

Protocol revision date: January 2005
Applies to all epithelial thymic neoplasms
No AJCC/UICC staging system

THYMOMA AND THYMIC CARCINOMA: Biopsy

Patient name:
Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC

Specimen Type
___ Fine-needle aspiration biopsy
___ Computed tomography-guided needle biopsy
___ Transthoracic needle biopsy
___ Limited thoracotomy
___ Other (specify): ____________________________
___ Not specified

Tumor Site
___ Thymus
___ Anterior mediastinum
___ Middle mediastinum
___ Posterior mediastinum
___ Other (specify): ____________________________
___ Not specified

* Data elements with *asterisks* are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.
MICROSCOPIC

Histologic Type
___ Type A thymoma (epithelial, spindle cell, medullary)
___ Type B thymoma, B1 (lymphocyte-rich, lymphocytic, predominantly cortical, organoid)
___ Type B thymoma, B2 (cortical)
___ Type B thymoma, B3 (epithelial, atypical, squamoid, well-differentiated thymic carcinoma)
___ Type AB thymoma (mixed)
___ Type C thymoma (thymic carcinoma), epidermoid keratinizing (squamous cell) carcinoma
___ Type C thymoma (thymic carcinoma), epidermoid nonkeratinizing carcinoma/
    lymphoepithelioma-like carcinoma
___ Type C thymoma (thymic carcinoma), sarcomatoid carcinoma
___ Type C thymoma (thymic carcinoma), carcinosarcoma
___ Type C thymoma (thymic carcinoma), clear cell carcinoma
___ Type C thymoma (thymic carcinoma), basaloid carcinoma
___ Type C thymoma (thymic carcinoma), mucoepidermoid carcinoma
___ Type C thymoma (thymic carcinoma), papillary carcinoma
___ Type C thymoma (thymic carcinoma), undifferentiated carcinoma
___ Other (specify): _____________________
___ Carcinoma, type cannot be determined

*Comment(s)
### Surgical Pathology Cancer Case Summary (Checklist)

*Protocol revision date: January 2005*

*Applies to all epithelial thymic neoplasms*

*No AJCC/UICC staging system*

---

**THYMOMA AND THYMIC CARCINOMA: Thymectomy, Other Procedure**

Patient name:
Surgical pathology number:

**Note: Check 1 response unless otherwise indicated.**

---

**MACROSCOPIC**

**Specimen Type**

- ___ Cervical thymectomy
- ___ Thoracotomy
- ___ Video-assisted thoracotomy
- ___ Other (specify): ____________________________
- ___ Not specified

*Specimen Size*

*Greatest dimension: ___ cm
*Additional dimensions: ___ x ___ cm

**Tumor Site**

- ___ Thymus
- ___ Anterior mediastinum
- ___ Middle mediastinum
- ___ Posterior mediastinum
- ___ Other (specify): ____________________________
- ___ Not specified

**Tumor Size**

Greatest dimension: ___ cm
*Additional dimensions: ___ x ___ cm
___ Cannot be determined (see Comment)
MICROSCOPIC

**Histologic Type**
- Type A thymoma (epithelial, spindle cell, medullary)
- Type B thymoma, B1 (lymphocyte-rich, lymphocytic, predominantly cortical, organoid)
- Type B thymoma, B2 (cortical)
- Type B thymoma, B3 (epithelial, atypical, squamoid, well-differentiated thymic carcinoma)
- Type AB thymoma (mixed)
- Type C thymoma (thymic carcinoma), epidermoid keratinizing (squamous cell) carcinoma
- Type C thymoma (thymic carcinoma), epidermoid non-keratinizing carcinoma/lymphoepithelioma-like carcinoma
- Type C thymoma (thymic carcinoma), sarcomatoid carcinoma
- Type C thymoma (thymic carcinoma), carcinosarcoma
- Type C thymoma (thymic carcinoma), clear cell carcinoma
- Type C thymoma (thymic carcinoma), basaloid carcinoma
- Type C thymoma (thymic carcinoma), mucoepidermoid carcinoma
- Type C thymoma (thymic carcinoma), papillary carcinoma
- Type C thymoma (thymic carcinoma), undifferentiated carcinoma
- Other (specify): ____________________
- Carcinoma, type cannot be determined

**Pathologic Staging**
- Stage I: Grossly and microscopically encapsulated
- Stage IIa: Microscopic transcapsular invasion
- Stage IIb: Macroscopic capsular invasion
- Stage III: Macroscopic invasion of neighboring organs
- Stage IVa: Pleural or pericardial dissemination
- Stage IVb: Hematogenous or lymphatic dissemination
- Cannot be determined

**Regional Lymph Nodes**
- Cannot be assessed
- No regional lymph node metastasis
- Regional lymph node metastasis
  Specify: Number examined: ___
  Number involved: ___

**Distant Metastasis**
- Cannot be assessed
- Distant metastasis
  *Specify site(s), if known: ____________________________

* Data elements with asterisks are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.
Margins
___ Cannot be assessed
___ Margins uninvolved by tumor
     Distance of tumor from closest margin: ___ mm
___ Margin(s) involved by tumor
     Specify margin(s): ____________________________

Invasion of Pulmonary Parenchyma
___ Cannot be assessed
___ Absent
___ Present
___ Indeterminate

Pleural Invasion
___ Cannot be assessed
___ Absent
___ Present
___ Indeterminate

*Vascular (Small/Large Vessel) Invasion
* ___ Absent
* ___ Present
* ___ Indeterminate

*Additional Pathologic Findings
*Specify: ____________________________

*Comment(s)